P. A. Gerus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
P. A. Gerus has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alyona L. Chernyshova
Institute of Oncology and Neurosurgery, E.N. Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, 630055 Novosibirsk, Russia
1 shared publication - Boris V. Sheplev
Institute of Chemical Biology and Fundamental Medicine Novosibirsk Russia
1 shared publication - Igor V. Maiborodin
Novosibirskii mediko-stomatologicheskii institut Dentmaster; Institute of Chemical Biology and Fundamental Medicine of Siberian Branch of the Russian Academy of Sciences
1 shared publication - L. L. Solovenchuk
Novosibirsk State Medical University of Minzdrav of Russia; Novosibirsk Regional Oncological Dispensary
1 shared publication - Sergey Fursov
Novosibirsk State Medical University, Ministry of Health of Russia
1 shared publication
Latest Publications
- Open Access
- 17 May 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (2) , 165-174
Colorectal cancer: angiogenesis and matrix metalloproteinases
Aim : to summarize the available literature data on the role of matrix metalloproteinases (MMPs) in angiogenesis, as well as in the development and progression of colorectal cancer (CRC). Material and Methods . A literature search was conducted in the Medline and eliBRARY.RU databases from 1999 to the present using the keywords “angiogenesis + cancer + colon + MMP”. Results. Malignant tumors are characterized by the ability to form new vessels, invade surrounding tissues, and metastasize to distant organs, and this aggressiveness depends on the expression of proteolytic enzymes, including MMPs. in CRC, the levels of MMPs are increased in both tumor tissues and blood plasma; these enzymes are required for extracellular matrix remodelling during angiogenesis, tumor invasion and metastasis. The degree of overexpression of certain MMPs correlates with the stage of CRC, vascularization, VEGF expression and/or prognosis; however, not all researchers agree with these findings. MMPs are synthesized both by tumor cells and, more prominently, stromal cells like tumor-associated macrophages. Alterations in the function of immunocompetent and stromal cells that express and produce MMPs play a key role in both the initiation and progression of CRC. Targeting tumor-associated immunocompetent and stromal cells, their reprogramming, neutralization and/or inhibition of their trafficking may delay the growth and invasion of CRC. inhibition of MMPs may represent one of the stages of antiangiogenic therapy. in addition to suppressing angiogenesis, certain MMP inhibitors stimulate apoptosis, suppress cell proliferation, induce cell cycle arrest, and reduce the expression of antiapoptotic genes of the Bcl family. A wide range of artificial and natural compounds and methods has been proposed as MMP inhibitors. However, despite promising experimental results, clinical trials of MMP inhibitors have been largely disappointing. There is evidence that some MMPs exert antitumor effects, and their blockade may be accompanied by tumor progression. Conclusion . A wide variety of approaches to targeting MMPs, together with the certain inconsistency of available data, may indicate the persisting dissatisfaction of researchers and clinicians with the current solutions to the problem of MMP-mediated angiogenesis in tumor tissues. This also highlights the need for continued investigation into both the effects of MMPs in CRC and the methods for controlling the activity of this enzyme group.
- 17 May 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (2) , 165-174
Open AccessColorectal cancer: angiogenesis and matrix metalloproteinases
Aim : to summarize the available literature data on the role of matrix metalloproteinases (MMPs) in angiogenesis, as well as in the development and progression of colorectal cancer (CRC). Material and Methods . A literature search was conducted in the Medline and eliBRARY.RU databases from 1999 to the present using the keywords “angiogenesis + cancer + colon + MMP”. Results. Malignant tumors are characterized by the ability to form new vessels, invade surrounding tissues, and metastasize to distant organs, and this aggressiveness depends on the expression of proteolytic enzymes, including MMPs. in CRC, the levels of MMPs are increased in both tumor tissues and blood plasma; these enzymes are required for extracellular matrix remodelling during angiogenesis, tumor invasion and metastasis. The degree of overexpression of certain MMPs correlates with the stage of CRC, vascularization, VEGF expression and/or prognosis; however, not all researchers agree with these findings. MMPs are synthesized both by tumor cells and, more prominently, stromal cells like tumor-associated macrophages. Alterations in the function of immunocompetent and stromal cells that express and produce MMPs play a key role in both the initiation and progression of CRC. Targeting tumor-associated immunocompetent and stromal cells, their reprogramming, neutralization and/or inhibition of their trafficking may delay the growth and invasion of CRC. inhibition of MMPs may represent one of the stages of antiangiogenic therapy. in addition to suppressing angiogenesis, certain MMP inhibitors stimulate apoptosis, suppress cell proliferation, induce cell cycle arrest, and reduce the expression of antiapoptotic genes of the Bcl family. A wide range of artificial and natural compounds and methods has been proposed as MMP inhibitors. However, despite promising experimental results, clinical trials of MMP inhibitors have been largely disappointing. There is evidence that some MMPs exert antitumor effects, and their blockade may be accompanied by tumor progression. Conclusion . A wide variety of approaches to targeting MMPs, together with the certain inconsistency of available data, may indicate the persisting dissatisfaction of researchers and clinicians with the current solutions to the problem of MMP-mediated angiogenesis in tumor tissues. This also highlights the need for continued investigation into both the effects of MMPs in CRC and the methods for controlling the activity of this enzyme group.